FR0010386334 - Common Stock
Taking everything into account, KORI scores 3 out of 10 in our fundamental rating. KORI was compared to 9 industry peers in the Health Care Providers & Services industry. KORI has a bad profitability rating. Also its financial health evaluation is rather negative. KORI has a correct valuation and a medium growth rate.
ROA (0.66%) VS Industry: 0% outperformed.
ROE (2.7%) VS Industry: 12% outperformed.
Profit Margin (2.28%) VS Industry: 12% outperformed.
Price/Earnings (20.32) VS Industry: 12% outperformed.
Price/Book (0.62) VS Industry: 87% outperformed.
Enterprise Value/ EBITDA (9.06) VS Industry: 66% outperformed.
Debt/Equity (2.04) VS Industry: 25% outperformed.
Quick Ratio (0.87) VS Industry: 50% outperformed.
Current Ratio (0.88) VS Industry: 25% outperformed.
Altman-Z (0.64) VS Industry: 12% outperformed.
Dividend Yield (1.78%) VS Industry: 42% outperformed.
EPA:KORI (5/16/2022, 5:29:41 PM)-0.18 (-0.87%)
|GICS Sector||Health Care|
|GICS IndustryGroup||Health Care Equipment & Services|
|GICS Industry||Health Care Providers & Services|
|Earnings (Last)||N/A N/A||Earnings (Next)||N/A N/A|
|Ins Owners||N/A||Inst Owners||N/A|
|PEG (NY)||1.16||PEG (5Y)||N/A|
|EPS 1Y||138.23%||EPS 3Y||-8.21%|
|EPS 5Y||-8%||EPS growth Q2Q||142.08%|
|EPS Next Y||17.52%||EPS Next 2Y||19.87%|
|EPS Next 3Y||18.62%||EPS Next 5Y||18.39%|
|Revenue growth 1Y||10.08%||Revenue growth 3Y||7.6%|
|Revenue growth 5Y||6.86%||Revenue growth Q2Q||10.97%|
|Revenue Next Year||7.89%||Revenue Next 2Y||7.27%|
|Revenue Next 3Y||6.98%||Revenue Next 5Y||6.38%|
|Current Ratio||0.88||Quick Ratio||0.87|
|Dividend Yield||1.78%||Dividend Growth||-14.2%|
Find stocks with similar Fundamental rating on the EuroNext
Find the competitors with the best fundamentals on the EuroNext
Find the competitors with the best valuation on the EuroNext
Find the competitors with the best dividend on the EuroNext